FindTrial
Sign In

Survival benefit on platinum based adjuvant chemotherapy following radical cystectomy for muscle invasive bladder cancer

Survival benefit on platinum based adjuvant chemotherapy following radical cystectomy for muscle invasive bladder cancer - Platinum based adjuvant chemotherapy following radical cystectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000021805
Enrollment
300
Registered
2016-04-07
Start date
2015-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle invasive bladder cancer

Interventions

None listed

Sponsors

Juntendo Nerima Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who performed the radical cystectomy for the invasive bladder cancer diagnosed with CT2-4aM0M0.

Exclusion criteria

Exclusion criteria: The patients who have lymph node metastasis and distant metastasis.

Design outcomes

Primary

MeasureTime frame
Overall survival—

Secondary

MeasureTime frame
Cancer-specific survival—

Countries

Japan

Contacts

Public ContactFumitaka Shimizu

Juntendo Nerima Hospital Urology

f_simizu@juntendo.ac.jp03-5923-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026